Bing He

Bing He

Auto-generated profile, based on publicly available information

Bing He


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDefang Li
Defang Li
JLJin Liu
Jin Liu
BGBaosheng Guo
Baosheng Guo
CLChao Liang
Chao Liang
LDLei Dang
Lei Dang
GZGe Zhang
Ge Zhang
Emerging evidence indicates that osteoclasts direct osteoblastic bone formation. MicroRNAs (miRNAs) have a crucial role in regulating osteoclast and osteoblast function. However, whether miRNAs mediate osteoclast-directed osteoblastic bone formation is mostly unknown. Here, we show that increased osteoclastic miR-214-3p associates with both elevated serum exosomal miR-214-3p and reduced bone formation in elderly women with fractures and in ovariectomized (OVX) mice. Osteoclast-specific miR-214-3p knock-in mice have elevated serum exosomal miR-214-3p and reduced bone formation that is rescued by osteoclast-targeted antagomir-214-3p treatment. We further demonstrate that osteoclast-derived exosomal miR-214-3p is transferred to osteoblasts to inhibit osteoblast activity in vitro and reduce bone formation in vivo. Moreover, osteoclast-targeted miR-214-3p inhibition promotes bone formation in ageing OVX mice. Collectively, our results suggest that osteoclast-derived exosomal miR-214-3p transfers to osteoblasts to inhibit bone formation. Inhibition of miR-214-3p in osteoclasts may be a strategy for treating skeletal disorders involving a reduction in bone formation.

21 November 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
LZLei-Ying Zheng
Lei-Ying Zheng
XGXiao-Sen Guo
Xiao-Sen Guo
BHBing He
Bing He
LSLian-Jun Sun
Lian-Jun Sun
YPYao Peng
Yao Peng
HJHai-Chun Jing
Hai-Chun Jing
Background: Sorghum (Sorghum bicolor) is globally produced as a source of food, feed, fiber and fuel. Grain and sweet sorghums differ in a number of important traits, including stem sugar and juice accumulation, plant height as well as grain and biomass production. The first whole genome sequence of a grain sorghum is available, but additional genome sequences are required to study genome-wide and intraspecific variation for dissecting the genetic basis of these important traits and for tailor-designed breeding of this important C4 crop. Results: We resequenced two sweet and one grain sorghum inbred lines, and identified a set of nearly 1,500 genes differentiating sweet and grain sorghum. These genes fall into ten major metabolic pathways involved in sugar and starch metabolisms, lignin and coumarin biosynthesis, nucleic acid metabolism, stress responses and DNA damage repair. In addition, we uncovered 1,057,018 SNPs, 99,948 indels of 1 to 10 bp in length and 16,487 presence/absence variations as well as 17,111 copy number variations. The majority of the large-effect SNPs, indels and presence/absence variations resided in the genes containing leucine rich repeats, PPR repeats and disease resistance R genes possessing diverse biological functions or under diversifying selection, but were absent in genes that are essential for life. Conclusions: This is a first report of the identification of genome-wide patterns of genetic variation in sorghum. High-density SNP and indel markers reported here will be a valuable resource for future gene-phenotype studies and the molecular breeding of this important crop and related species.

1 December 2017 in Biomaterials
Verified
Journal Article
Closed access
CLChao Liang
Chao Liang
LFLi Fangfei
Li Fangfei
LWLuyao Wang
Luyao Wang
ZZZong-Kang Zhang
Zong-Kang Zhang
CWChao WANG
Chao WANG
GZGe Zhang
Ge Zhang

7 September 2016 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
BHBing He
Bing He
CLCheng Lu
Cheng Lu
GZGuang Zheng
Guang Zheng
XHXiaojuan He
Xiaojuan He
MWMaolin Wang
Maolin Wang
ALAiping Lu
Aiping Lu
The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

Verified
Journal Article
Open access
PDF file
ASATIK BADSHAH SHAIKH
ATIK BADSHAH SHAIKH
FLFangfei Li
Fangfei Li
MLMin LI
Min LI
BHBing He
Bing He
XHXiaojuan He
Xiaojuan He
GZGe Zhang
Ge Zhang
Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma.

1 May 2019 in Journal of Proteomics
Verified
Journal Article
Closed access
BHBing He
Bing He
JSJian Shi
Jian Shi
XWXinwen Wang
Xinwen Wang
Hui JiangHui Jiang
Hui Jiang
HZHao-Jie Zhu
Hao-Jie Zhu